Research work · 2026

Cannabinoid Pharmacology and Neuroinflammation

Cassyni

Abstract

The endocannabinoid system (ECS) has emerged as a key regulator of brain function, especially in the context of stress, neuroinflammation, and emotional behavior. In this seminar I will explore the interface between cannabinoid pharmacology and neuroimmunology. The presentation will begin with an introduction to the ECS, highlighting its distinctive features as an “atypical neurotransmitter” system, its expression in both neurons and glial cells, and its role in modulating stress responses and fear conditioning. I will then present experimental evidence showing that stress exposure in rodents induces a neuroinflammatory profile in stress-related brain regions that can be modulated by cannabinoids. Further mechanistic insight comes from studies using genetically modified mice that exhibit PTSD-like phenotypes, and pharmacological strategies promoting FAAH inhibition or TRPV1 antagonism. Last, but not least, I will present evidence on the possible involvement of ECS in the anti-stress effect induced by inhibition of immune system molecules. Despite challenges in translating animal models to humans, our data and results from many other groups consistently support the view that cannabinoids modulate stress responses at least partly through immune-mediated mechanisms. By the end of the seminar, I expect to have provided a comprehensive update on how ECS-targeted strategies may open new avenues for treating stress-related neuropsychiatric disorders such as PTSD, and on the potential role of immune mechanisms in these effects.

DOI: 10.52843/cassyni.sdkwmh